Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - Preliminary study

Central European Journal of Immunology

Volumn 40, Issue 3, 2015, Pages 354-359

  Rudnicka, Julia ^a   Czerwiec, Michał ^a   Grywalska, Ewelina ^a   Siwicka Gieroba, Dorota ^a   Walankiewicz, Monika ^a   Grafka, Agnieszka ^b   Zgurski, Michał ^a   Surdacka, Agata ^a,b   Bartosik Psujek, Halina ^a   Roliñski, Jacek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b ST JOHN S CANCER CENTER   (Poland)

Author keywords

Fingolimod; Lymphocytes T; MS; Multiple sclerosis; T CD4+:T CD8+ cells ratio

Indexed keywords

FINGOLIMOD; FLUOROCHROME; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG USE; FEMALE; FLOW CYTOMETER; HUMAN; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL;

EID: 84944520592     PISSN: 14263912     EISSN: 16444124     Source Type: Journal    
DOI: 10.5114/ceji.2015.54599     Document Type: Article

References (36)

1. Jaskiewicz E (2004): Epitopes on myelin proteins recognized by autoantibodies present in multiple sclerosis patients. Po-stepy Hig Med Dosw 58: 472-482.
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000): Multiple sclerosis. N Engl J Med 343: 938-952.
3. O'Connor KC, Bar-Or A, Hafler DA (2001): The neuroim-munology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 21: 81-92.
4. Zawada M (2012): Potential pathogens in multiple sclerosis (MS). Postepy Hig Med Dosw 66: 758-770.
5. Dalakas MC (2006): B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther 112: 57-70.
6. Goverman J (2009): Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 9: 393-407.
7. Lalive PH (2008): Autoantibodies in inflammatory demye-linating diseases of the central nervous system. Swiss Med Wkly 138: 692-707.
8. Lis J, Jarzab A, Witkowska D (2012): Rola mimikry mo-lekularnej w etiologii schorzen o charakterze autoimmuni-zacyjnym. Postepy Hig Med Dosw 66: 475-491.
9. Gbadamosi J, Buhmann C, Tessmer W, et al. (2003): Effects of mitoxantrone on multiple sclerosis patients lymphocyte subpopulations and production of immunoglobulin, TNF-al-pha and IL-10. Eur Neurol 49: 137-141.
10. Goffette S, van Pesch V, Vanoverschelde JL, et al. (2005): Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J Neurol 252: 1217-1222.
11. Fox EJ (2004): Mechanism of action of mitoxantrone. Neurology 63: 15-18.
12. Szwed M (2014): Mitoxantrone-an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis. Postepy Hig Med Dosw 68: 198-208.
13. Bayas A (2013): Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv 10: 285-287.
14. Nogales-Gaete J, Aracena R, Díaz V (2012): Neuropsycho-logical assessment of patients with relapsing remitting multiple sclerosis prior to the use of immunomodulatory drugs. Rev Med Chil 140: 1437-1444.
15. Cruz VT, Fonseca J (2014): Central effects of fingolimod. Rev Neurol 59: 121-128.
16. Groves A, Kihara Y, Chun J (2013): Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 328: 9-18.
17. Chun J, Hartung HP (2010): Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neurophar-macol 33: 91-101.
18. Waters L, Mandalia S, Randell P, et al. (2008): The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 46: 1617-1623.
19. Piwowar A (2014): The advanced oxidation protein products as potential diagnostic and prognostic factor in diseases of the indicated participation of oxidative stress. Postepy Hig Med Dosw (Online) 68: 446-458.
20. Hotchkiss RS, Tinsley KW, Swanson PE, et al. (2001): Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166: 6952-6963.
21. Pelekanou A, Tsangaris I, Kotsaki A, et al. (2009): Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study. Crit Care 13: R172.
22. Gupta M, Spiropoulou C, Rollin PE (2007): Ebola virus infection of human PBMCs causes massive death of macro-phages, CD4 and CD8 T cell sub-populations in vitro. Virology 364: 45-54.
23. Konikowska K, Regulska-Ilow B (2014): The role of diet in multiple sclerosis. Postepy Hig Med Dosw (Online) 68: 325-333.
24. Wikby A, Maxson P, Olsson J, et al. (1998): Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study. Mech Ageing Dev 102: 187-198.
25. De Paoli P, Battistin S, Santini GF (1988): Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol 4: 290-296.
26. Walker UA, Warnatz K (2006): Idiopathic CD4 lymphocyto-penia. Curr Opin Rheumatol 18: 389-395.
27. Cohen JA, Barkhof F, Comi G, et al. (2010): Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415.
28. Uccelli A, Ginocchio F, Mancardi GL, Bassetti M (2011): Primary varicella zoster infection associated with fingolimod treatment. Neurology 76: 1023-1024.
29. Gross CM, Baumgartner A, Rauer S, Stich O (2012): Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology 79: 2006-2007.
30. Ratchford JN, Costello K, Reich DS, Calabresi PA (2012): Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 79: 2002-2004.
31. Ricklin ME, Lorscheider J, Waschbisch A, et al. (2013): T-cell response against varicella-zoster virus in fingoli-mod-treated MS patients. Neurology 81: 174-181.
32. Cervera C (2012): Infections and fingolimod. Rev Neurol 55: 227-237.
33. Soliman DS, Sabbagh AA, Omri HE (2014): Rare aggressive natural killer cell leukemia presented with bone marrow fi-brosis-a diagnostic challenge. Springerplus 3: 390.
34. Ligthart GJ, van Vlokhoven PC, Schuit HR, Hijmans W (1986): The expanded null cell compartment in ageing: increase in the number of natural killer cells and changes in T-cell and NK-cell subsets in human blood. Immunology 59: 353-357.
35. Krishnaraj R, Blandford G (1988): Age-associated alterations in human natural killer cells. 2. Increased frequency of selective NK subsets. Cell Immunol 114: 137-148.
36. Adamiak M, Tokarz-Deptuła B, Deptuła W (2014): Characteristic of innate lymphoid cells (ILC). Postepy Hig Med Dosw (Online) 68: 1464-1471.